Healthcare Professional Information
Rebif® Pregnancy Registry

March 2005: We would like to inform you that Serono, Inc. and Pfizer Inc, co-marketers of Rebif® (interferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS), are conducting a Pregnancy registry to determine the safety of Rebif in women who are pregnant or who may become pregnant. The FDA mandates these programs for many products due to the limited data on this patient population obtained during premarketing clinical trials.

The Rebif Pregnancy Registry program will enroll women who are in the first trimester of pregnancy and who were treated with Rebif within one week prior to becoming pregnant or during pregnancy. The Rebif Pregnancy Registry collects and assesses postmarketing data on outcomes of exposure to Rebif in pregnant women with MS, their fetuses, and/or live born infants. These outcomes will be compared to outcomes of a control group of women with MS who have not been exposed to Rebif or any other interferon during pregnancy.

The program is designed to make it quick and convenient for you and your staff to provide important information to MS patients who have been exposed to/treated with Rebif during pregnancy. Investigator responsibilities include obtaining informed consent, registering the patient, and providing pregnancy outcome data. You will receive a reminder e-mail/fax within one month following the anticipated due date.

Your participation and that of your patients is essential to developing and completing the Rebif Pregnancy Registry and evaluating pregnancy outcomes. We thank you in advance for your assistance.

How to enroll:

If a pregnant MS patient under your care may be eligible for enrollment in either the Rebif arm or the control arm of the registry, please contact the Rebif Pregnancy Registry at www.rebifpregnancyregistry.com or call, MS LifeLines at 1-877-44-REBIF (1-877-447-3243).

3/05